Clinicopathological factors associated with the presence of tumor deposits in resected gastric cancer patients

Torres, O.R. Paredes; Prado-Cucho, Sofía; Taxa, Luis; Luque-Vasquez, Carlos; Chavez, Ivan; Meza, Eduardo Payet; Figueroa, Eloy Ruiz; Espinoza, Francisco Berrospi

doi:10.1016/j.heliyon.2021.e07185

Cited by 4 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In eastern Asia, the standard approach is surgical resection with D2 lymphadenectomy, followed by adjuvant chemotherapy, whereas in Western countries there is a preference for using either perioperative chemotherapy or postoperative chemoradiation, especially in cases of inadequate (<D2) lymph node dissection [ 7 ]. In our country, adjuvant chemotherapy after D2 lymph node dissection is considered the standard treatment and the postoperative morbidity and mortality in D2 radical gastrectomy for gastric cancer in Peruvian patients are 23.3% and 3.3%, respectively [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer

Serrano¹,

Araujo²,

Pacheco³

et al. 2022

ecancer

Self Cite

View full text Add to dashboard Cite

Background Gastric cancer (GC) is the fourth most common cause of cancer deaths around the world and the first cause of cancer deaths in Peru; however, there are no prospective trials for adjuvant chemotherapy in GC after curative gastrectomy in this country. The objective of this study was to evaluate the effectiveness of adjuvant chemotherapy in stage II–III gastric cancer patients who underwent D2 gastrectomy. Methods We included patients with stage II–III gastric cancer who underwent radical gastrectomy and D2 dissection between 2014 and 2016 at our institution. Patients received 3-week cycles of capecitabine (1,000 mg/m 2 twice daily on days 1–14) plus oxaliplatin (130 mg/m 2 on day 1) for 6 months. Survival curves were estimated with the Kaplan–Meier method, and the Cox proportional hazards model was used to identify prognostic factors for survival. Results In total, 173 patients were included: 100 (57.8%) patients received adjuvant chemotherapy and surgery (AChS) and 73 (42.2%) surgery alone (SA). Three-year disease-free survival (DFS) was higher in the AChS groups (69%) than in the SA group (52.6%) ( p = 0.034). Regarding overall survival (OS), 31 patients (31%) died in the AChS group compared with 34 (46.6%) in the SA group ( p = 0.027). In the multivariate analysis, adjuvant chemotherapy was an independent prognostic factor for DFS (HR = 0.60; 95% CI = 0.37–0.97; p = 0.036) and OS (HR = 0.58; 95% CI = 0.36–0.95; p = 0.029). ACh showed consistent benefit in DFS and OS for patients with albumin >3.5 g/dL, lymphovascular and perineural invasion, pT4, pN2–3, pathologic stage (PS) IIIA and IIIB and lymph node ratio (LNR) > 13.1. Conclusion These data suggest that adjuvant capecitabine and oxaliplatin reduce the recurrence and mortality in patients with stage II–III gastric cancer who underwent D2 gastrectomy. PS IIIA and IIIB and LNR > 13.1 benefited more from receiving adjuvant chemotherapy and poorly cohesive gastric carcinoma did not significantly reduce the rates of survival.

show abstract

Section: Introductionmentioning

confidence: 99%

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer

Serrano¹,

Araujo²,

Pacheco³

et al. 2022

ecancer

Self Cite

View full text Add to dashboard Cite

show abstract

Prognostic effect of categorized tumor deposits in gastric cancer: A single-center retrospective study

Hayashi,

Abe,

Fujita

et al. 2024

Surgery

View full text Add to dashboard Cite

Prognostic significance of tumor deposits in radically resected gastric cancer: a retrospective study of a cohort of 1915 Chinese individuals

et al. 2022

View full text Add to dashboard Cite

Background Tumor deposits (TDs) have been identified as an independent prognostic factor in gastric cancer (GC). However, the associated clinicopathological factors and how to simply and reasonably incorporate TD into the TNM staging system remain undetermined. The aim of the current study was therefore to assess the significance of TD among radically resected GC patients. Methods We retrospectively reviewed 1915 patients undergoing radical resection between 2007 and 2012. The patients were classified into two groups according to TD status (absent vs. present), and the clinicopathologic characteristics, DFS, and OS were compared. Associations of TD presence with other clinicopathologic factors were evaluated by logistic regression analysis. Univariate and multivariate Cox regression analyses were performed to determine the prognostic factors for DFS and OS in the primary cohort. Propensity score matching (PSM) was performed to reduce the possibility of selection bias according to the presence of TD. External validation of previously proposed modified staging systems incorporating TD was conducted. Results The detection rate of TD was 10.5% (201/1915). The presence of TD was significantly related to unfavorable clinicopathologic variables, including advanced T and N categories. According to the multivariate Cox regression analysis, the presence of TD was identified as an independent prognostic factor for DFS and OS in the primary cohort (both P < 0.001). In the after-PSM cohort, TD presence also significantly shortened DFS and OS. In the external validation, one system that incorporated TD into the pTNM stage had the best performance. Conclusions The presence of TD was significantly associated with poor survival in radically resected GC patients. The incorporation of TD into the TNM staging system can further improve the predictive capability. A multicenter cohort with a large sample size is needed to determine the appropriate method of incorporation.

show abstract

Clinicopathological factors associated with the presence of tumor deposits in resected gastric cancer patients

Cited by 4 publications

References 30 publications

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer

Prognostic effect of categorized tumor deposits in gastric cancer: A single-center retrospective study

Prognostic significance of tumor deposits in radically resected gastric cancer: a retrospective study of a cohort of 1915 Chinese individuals

Contact Info

Product

Resources

About